Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | MCOLN3 | Q8TDD5 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2333476 | 0.77 | DRD2 (0.45) | ARMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL12444394 | 0.76 | AR (0.50) | ARMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL29948080 | 0.74 | MAPT (0.48) | MEN1KMT2AALDH1A1MCOLN3LMNA | |
| SCHEMBL28665110 | 0.74 | MAPT (0.48) | MEN1KMT2AALDH1A1MCOLN3LMNA | |
| SCHEMBL12444391 | 0.71 | MAPT (0.58) | MEN1KMT2AALDH1A1MCOLN3LMNA | |
| SCHEMBL16702383 | 0.71 | AR (0.54) | ARMEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL12445267 | 0.70 | PIK3CA (0.46) | MEN1KMT2AALDH1A1MCOLN3LMNA | |
| SCHEMBL12444389 | 0.70 | LMNA (0.58) | MEN1KMT2AALDH1A1MCOLN3LMNA | |
| SCHEMBL14840552 | 0.70 | AR (0.47) | ARRAB9ASMN1; SMN2 | |
| SCHEMBL16264819 | 0.69 | AR (0.52) | ARMEN1KMT2AALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130053372-A1 | 5-HT RECEPTOR MODULATORS | CAMBRIDGE ENTERPRISE LIMITED | 2013-02-28 | — | — | US | disclosed |
| US-20130053372-A1 | 5-HT RECEPTOR MODULATORS | CAMBRIDGE ENTERPRISE LIMITED | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053372-A1 | 5-HT RECEPTOR MODULATORS | HTR1B, HTR5A, HTR1A | AR 799/4885MEN1 1036/4885KMT2A 2405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.